Wells Fargo Downgrades Cabaletta Bio(CABA.US) to Hold Rating, Cuts Target Price to $6
Evercore Initiates Cabaletta Bio(CABA.US) With Hold Rating, Announces Target Price $6
Analysts Conflicted on These Healthcare Names: Verastem (VSTM), Roche Holding AG (OtherRHHVF) and Cabaletta Bio (CABA)
BofA Securities Cuts Price Target on Cabaletta Bio to $29 From $31, Keeps Neutral Rating
Cabaletta Bio Cut to In-Line From Outperform by Evercore ISI Group
Evercore ISI Group Downgrades Cabaletta Bio to In-Line, Lowers Price Target to $6
104742610 : not sure
104742610 : hold for long term